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Abstract 
EPR spectra were recorded for methionine aminopeptidase from Escherichia coli (EcMetAP-I) samples 
(~2.5 mM) to which one and two equivalents of Mn(II) were added (the latter is referred to as 
[MnMn(EcMetAP-I)]). The spectra for each sample were indistinguishable except that the spectrum of 
[MnMn(EcMetAP-I)] was twice as intense. The EPR spectrum of [MnMn(EcMetAP-I)] exhibited the 
characteristic six-line g≈2 EPR signal of mononuclear Mn(II) with Aav(55Mn)=9.3 mT (93 G) and exhibited 
Curie-law temperature dependence. This signal is typical of Mn(II) in a ligand sphere comprising oxygen 
and/or nitrogen atoms. Other features in the spectrum were observed only as the temperature was 
raised from that of liquid helium. The temperature dependences of these features are consistent with 
their assignment to excited state transitions in the S=1, 2 ... 5 non-Kramer’s doublets, due to two 
antiferromagnetically coupled Mn(II) ions with an S=0 ground state. This assignment is supported by the 
observation of a characteristic 4.5 mT hyperfine pattern, and by the presence of signals in the parallel 
mode consistent with a non-Kramers’ spin ladder. Upon the addition of the anti-angiogenesis agent 
fumagillin to [MnMn(EcMetAP-I)], very small changes were observed in the EPR spectrum. MALDI-TOF 
mass spectrometry indicated that fumagillin was, however, covalently coordinated to EcMetAP-I. 
Therefore, the inhibitory action of this anti-angiogenesis agent on EcMetAP-I appears to involve 
covalent binding to a polypeptide component at or near the active site rather than direct binding to the 
metal ions. 
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Introduction 
Methionyl aminopeptidases (MetAPs) represent a unique class of protease that is capable of the 
hydrolytic removal of an N-terminal methionine residue from nascent polypeptide chains.1,2,3,4 In both 
eukaryotic and prokaryotic cells, MetAPs selectively cleave methionine residues from the N-termini of 
polypeptide chains. In the cytosol of eukaryotes, all proteins are initiated with an N-terminal methionine 
residue, whereas in prokaryotes, mitochondria, and chloroplasts, translation of proteins is initiated with 
an N-formyl methionine.2,5,6,7 The N-formyl group is typically removed cotranslationally by a deformylase 
that leaves the N-terminal methionine with a free NH2 group.8 Removal of methionine is essential for 
protein maturation as well as for the post-translational modification of the N-termini of proteins, such 
as N-acetylation or N-myristoylation. Deletion of the gene encoding MetAP is lethal toEscherichia 
coli, Salmonella typhimurium, and Saccharomyces cerevisiae; therefore, MetAPs are essential for cell 
growth and proliferation.9,10,11,12 The importance of understanding the catalytic mechanism of MetAPs is 
underscored by the recent observation that MetAPs are the target for anti-cancer drugs, one of which is 
in the third stage clinical trials.13 Thus, the design of mechanism-based inhibitors is critically important in 
the development of drugs that prevent tumor growth and proliferation. 
MetAPs are organized into two classes (types I and II) based on the absence or presence of an extra 62 
amino acid sequence (of unknown function) inserted near the catalytic domain. The type-I MetAPs 
from E. coli (EcMetAP-I) and Staphylococcus aureus (SaMetAP-I) and the type-II MetAPs from Homo 
sapiens (HsMetAP-II) and Pyrococcus furiosus (PfMetAP-II) have been crystallographically 
characterized.14,15,16,17,18 All display a novel “pita-bread” fold with an internal pseudo-two-fold symmetry 
that structurally relates the first and second halves of the polypeptide chain to each other. Each half 
contains an antiparallel β-pleated sheet flanked by two helical segments and a C-terminal loop. Both 
domains contribute conserved residues to the metalloactive site. In each structure, a bis(μ-
carboxylato)(μ-aqua/hydroxo)dicobalt core is observed, with an additional carboxylate residue at each 
metal site and a single histidine bound to cobalt 1 (Co1). Based on activity measurements, all of these 
enzymes have been proposed to be Co(II)-dependent enzymes.16,19 However, it has been shown that 
the addition of either Co(II), Fe(II), or Mn(II) provides enzymes that are catalytically competent.20 More 
recently, EcMetAP-I was shown to exhibit maximum catalytic activity with only one equivalent of either 
Co(II) or Fe(II).20 The catalytically competent metal ion, assigned to M1, is ligated by His171 according 
to 1H NMR and EXAFS data.20,21 Based on these data, it was suggested that either Fe(II) or Mn(II) is the 
physiologically relevant metal ion and that all MetAPs function as a mononuclear metallohydrolase in 
vivo.22,23 Interestingly, EcMetAP-I can bind up to two equivalents of Mn(II), providing an enzyme that 
exhibits ~20% of the activity observed with Co(II)24,25 and a team at Abbott Laboratories recently 
suggested that the physiologically relevant metal ion for HsMetAP-II is Mn(II).23 
Type-II MetAPs have been shown to be the target for the sesquiterpene epoxide-containing anti-
angiogenesis agents ovalicin, fumagilin, and TNP-470, the last of which is currently in phase III clinical 
trials.13,17,26,27,28 Type-I MetAPs have also been shown to covalently bind fumagilin through an active-site 
histidine residue which is identical to type-II MetAPs, albeit more slowly.28 A significant aspect of 
designing small molecules that specifically target MetAPs is to gain a detailed understanding of how 
fumagillin, a covalently linked inhibitor, interacts with MetAPs. The X-ray crystal structure HsMetAP-II 
complexed with fumagillin indicated that fumagillin covalently binds to an active-site histidine residue.17 
In addition, it was suggested that an alkoxide moiety on fumagillin, that resides 3.28 Å from an active-
site metal ion, binds to the dinuclear active site. Herein, we demonstrate that Mn(II)-loaded EcMetAP-I 
forms a bona fide dinuclear Mn(II) site. We also provide evidence that the mode of binding of fumagillin 
to EcMetAP-I is analogous to that in HsMetAP-II except that the alkoxide moiety on fumagillin is not an 
active-site ligand. 
Materials and methods 
Protein expression and purification 
All chemicals used in this study were purchased commercially and were of the highest quality available. 
Recombinant wild-type EcMetAP-I was expressed and purified as previously described.20,25 
Purified EcMetAP-I exhibited a single band on SDS-PAGE and a single symmetrical peak in matrix-
assisted laser desorption ionization time-of-flight (MALDI-TOF) spectrometric analysis, 
indicating Mr=29,630±10. Protein concentrations were estimated from the absorbance at 280 nm using 
an extinction coefficient of 16,450 M−1 cm−1. Apo-EcMetAP-I samples were exchanged into 25 mM Hepes 
(pH 7.5) containing 150 mM KCl (Centricon-10, Millipore). The protein was washed free of methionine 
using Chelex-treated methionine-free buffer (25 mM Hepes, pH 7.5, 150 mM KCl) prior to all kinetic 
assays. Samples of apo-EcMetAP-I were routinely concentrated by microfiltration using a Microcon-10 
concentrator (Amicon, Beverly, Mass., USA) and individual aliquots were stored in liquid nitrogen until 
needed. 
Enzymatic assay 
EcMetAP-I was assayed for catalytic activity with the tetrapeptide MGMM as the substrate (8 mM) using 
an HPLC method as previously described.20 This method is based on the spectrophotometric 
quantitation of the reaction product GMM following separation on a C8 HPLC column (Phenomenex, 
Luna; 5μ, 4.6×25 cm). The kinetic parameter v (velocity) was determined at pH 7.5 by quantifying the 
tripeptide GMM at 215 nm in triplicate. One unit of activity is defined as the amount of enzyme that 
produces 1 μmol of GMM in 1 min. The hydrolysis of MP-p-NA was monitored spectrophotometrically at 
405 nm, based on the increase in absorbance of p-NA (Δε405 value of p-nitroaniline of 10,600 M−1 cm−1) 
using a coupled assay.29 The reaction mixture consisted of a 5-μL aliquot of a 10-μM enzyme solution, 
3 μL of 2.0 mM prolidase in 20 mM Tris containing 30% glycerol. Various concentrations of substrate 
were added to the enzyme solution to a final volume of 1000 μL (25 mM Hepes in Chelexed water at 
pH 7.5 containing 150 mM KCl). Enzyme activities are expressed as units/mg, where one unit is defined 
as the amount of enzyme that releases 1 μmol of product at 30 °C in 1 min. Catalytic activities were 
determined with an error of ±10%. 
Fumagillin-bound forms of [MnMn(EcMetAP-I)] 
Samples of [MnMn(EcMetAP-I)]+fumagillin were prepared by the method of Lowther et al. [28]. Briefly, 
a 2.5 mM [MnMn(EcMetAP-I)] sample in 25 mM Bicine buffer (pH 7.5) and 150 mM KCl was reacted with 
10 equiv of fumagillin (Sigma, dissolved in dimethyl sulfoxide) under anaerobic conditions and frozen. 
[MnMn(EcMetAP-I)]-fumagillin EPR samples were analyzed by MALDI on a linear time-of-flight mass 
spectrometer (TOF-MS) equipped with delayed ion extraction.30,31 An ion source bias voltage of 24 kV 
and an extraction delay time of 1050 ns were employed. Ion extraction pulse voltages were selected to 
optimize mass resolution (via time lag focusing) for the largest m/z ion of interest in each sample. The 
ion signals generated from 100 individual laser shots (337 nm) were signal averaged to generate the 
resulting MALDI spectra. MALDI spectra were externally mass calibrated by the use of the flight times 
and known masses of the singly and doubly protonated ions produced by MALDI from a sample 
ofEcMetAP-I. [MnMn(EcMetAP-I)]-fumagillin samples in Bicine buffer (pH 7.5) and 150 mM KCl were 
initially run down a C4 ZipTip (Millipore, Bedford, Mass., USA) prior to MALDI analysis to remove excess 
buffer and salts. The ZipTip was first treated with 30 μL of a 75% acetonitrile/25% distilled, deionized 
(DDI) water solution followed by 40 μL of a 0.1% trifluoroacetic acid (TFA) in DDI water solution. The 
[MnMn(EcMetAP-I)]-fumagillin sample utilized for EPR analysis was diluted 20:1 with DDI water. Four 
successive 10-μL aliquots of the diluted protein sample were aspirated over the C4 modified silica 
packing of the ZipTip using a micropipette in order to bind proteins in the sample to the modified silica 
surface. Subsequent to binding, the ZipTip was washed with five successive 10-μL aliquots of 0.1% TFA in 
DDI water solution to remove the Bicine buffer and any other contaminating salts. The bound proteins 
were released from the ZipTip utilizing a 25 mM solution of 4-hydroxy-α-phenylcinnamic acid (Aldrich, 
Milwaukee, Wis., USA) prepared in 75% acetonitrile/25% DDI water with 0.1% TFA. A single 6-μL volume 
of the 4-hydroxy-α-phenylcinnamic acid was successively aspirated over the C4 modified silica packing of 
the ZipTip and 3 μL of this solution was deposited after the fourth aspiration onto the MALDI sample 
target and the solution allowed to evaporate. The non-volatile 4-hydroxy-α-phenylcinnamic acid served 
as the UV absorbing matrix for subsequent MALDI analysis. 
Spectroscopic measurements 
Low-temperature dual-mode EPR spectroscopy was carried out as in earlier work32,33 using a Bruker ESP-
300E spectrometer equipped with an ER 4116 DM dual-mode X-band cavity and an Oxford Instruments 
ESR-900 helium flow cryostat. EPR spectra were recorded at a modulation frequency of 100 kHz and at 
microwave frequencies of about 9.65 GHz and 9.37 GHz for perpendicular and parallel modes, 
respectively. Precise microwave frequencies were recorded for individual spectra to ensure precise g-
alignment and all spectra and simulations are presented with respect to a magnetic field range 
corresponding to a microwave frequency of 9.646000 GHz. Other EPR recording parameters are 
specified in the figure legends. 
Results 
EPR spectroscopy of Mn(II)-substituted EcMetAP-I 
EPR spectra were recorded for EcMetAP-I samples (~2.5 mM) to which one and two equivalents of 
Mn(II) were added (referred to as [MnMn(EcMetAP-I)]). The spectra for each sample were 
indistinguishable except that the spectrum of [MnMn(EcMetAP-I)] was twice as intense as that 
of EcMetAP-I to which one equivalent of Mn(II) had been added.34 Activity measurements showed a 
linear increase in activity with added Mn(II) up to 2.7±0.3 equiv.24 An EPR spectrum recorded at 4 K on a 
2.5-mM sample of [MnMn(EcMetAP-I)] in Bicine buffer (pH 7.5) exhibited the characteristic six-line g≈2 
EPR signal of mononuclear Mn(II) (Fig. 1a). This signal was centered at g=2.02 (341 mT) and the I=5/2 
hyperfine lines due to 55Mn exhibited Aav(55Mn)=9.3 mT (93 G). This is typical of Mn(II) in a ligand sphere 
composed of oxygen and/or nitrogen atoms.35 That the signal is not due to uncomplexed Mn(II) can be 
clearly seen by comparison with the EPR signal observed at 4 K upon the addition of 5 mM MnCl2 in 
Bicine buffer (pH 7.5) (Fig. 1c). Also evident in the spectrum of [MnMn(EcMetAP-I)] is a six-line pattern 
centered at g=4.15 (166 mT) with Aav(55Mn)≈9.0 mT. This signal is often attributed to Δms=2 transitions 
that are formally forbidden for systems of high symmetry.35,36,37 Other features in the spectrum include a 
weak six-line pattern centered at g=9.0 (77 mT) with Aav(55Mn)≈9.0 mT (part of which is shown 
magnified above Fig. 1a) and a signal extending out of zero field with poorly defined features that is 
again separated by ~9 mT. These features, in other systems, have been presumed to be due to inter-
Kramer’s doublet “fine structure” transitions where ms=±5/2↔±3/2 and ms=±3/2↔±1/2.38 Thus, at 4 K, 
all of the spectral features can be attributed to a mononuclear Mn(II) species associated with EcMetAP-I. 
 
Fig. 1. EPR spectra of: (a) 2.5 mM [MnMn(EcMetAP)] sample at 4 K, (b) 2.5 mM [MnMn(EcMetAP)] sample at 41 K, 
(c) 5 mM MnCl2 buffered solution at 4 K, and (d) 5 mM MnCl2 buffered solution at 41 K. All samples were prepared 
in 25 mM Bicine buffer (pH 7.5) and 150 mM KCl. Spectra were recorded using 2.0 mW (a, b) or 5.0 mW (c, d) 
microwave power and 0.8 mT modulation amplitude. The intensities of spectra band d are shown comparative 
to a and c, respectively, after corrections for receiver gain differences and temperature. The insert above trace a, 
centered at 77 mT, is magnified 200 times 
At higher temperatures, additional transitions were observed that cannot be accounted for by 
mononuclear Mn(II). An EPR spectrum of a 2.5 mM [MnMn(EcMetAP-I)] sample recorded at 41 K 
(Fig. 1b) was found to clearly exhibit a number of transitions in addition to those observed at 4 K. The 
most intense of these additional transitions have resonance positions at geff=3.19 (216 mT), 2.85 
(242 mT), 2.39 (289 mT), and 1.60 (430 mT). Weaker transitions are seen as a shoulder at geff=1.43 
(482 mT), as a broad peak centered at geff=1.31 (526 mT), and as a broad absorption extending out of 
zero field. Additional structure observed in the g=2 region can occur because of forbidden transitions 
and g anisotropy due to a lower symmetry environment for Mn(II) when bound as monomeric Mn(II) in 
either a dinuclear active site or bound to the protein in a third, distinct or adventitious site. Since 
quantitation of these signals is difficult, at this time we were unable to accurately quantitate the amount 
of Mn(II) in the sample that accounts for these high-temperature signals. The appearance of these 
features at high temperature, and at unusual geff values, suggests that these signals are due to an 
excited state transition(s) in the S=1, 2 ... 5 non-Kramer’s doublets due to two antiferromagnetically 
coupled Mn(II) ions with an S=0 ground state.39,40 Closer inspection of the feature at g≈2.39 provided 
further evidence for the signals being due to a dinuclear species. Figure 2 shows the spectrum of a 
2.5 mM [MnMn(EcMetAP-I)] sample recorded at 41 K between 250 and 450 mT. Multiline hyperfine 
structure with a splitting of 4.4 mT can clearly be seen on the feature atgeff=2.39 (289 mT), extending 
from 260 to 310 mT. These splittings are characteristic of exchange-coupled Mn(II) ions35 and are a good 
indication that the additional features seen at 41 K are due to non-Kramer’s doublet excited-state 
transitions due to spin-coupled Mn(II) ions. 
 
Fig. 2. EPR spectra of Mn(II)-loaded EcMetAP-I in 25 mM Bicine buffer (pH 7.5) and 150 mM KCl at 41 K: 250–440 
mT region of EcMetAP-I with (a) one equivalent of Mn(II) and (b) two equivalents of Mn(II) added. Fourier filtering 
of the spectrum provides the traces above a and b. These data have been magnified 20 times, highlighting the 4.4-
mT-split multiline signals 
Final confirmation that the unusual signals seen at high temperature are due to an integer spin system 
was sought using parallel-mode EPR spectroscopy. Parallel-mode spectra recorded on [MnMn(EcMetAP-
I)] are presented in Fig. 3. At 4 K (Fig. 3a), the signal is dominated by an intense absorption emerging out 
of zero field and the transition is similar in appearance to that seen in the perpendicular mode. Both the 
perpendicular and parallel mode features exhibit a temperature dependence that follows Curie’s law at 
low temperature but the signals decay rapidly at high temperature (parallel mode spectra are shown 
recorded at 4, 10, 41, and 70 K in Fig. 3a–d, respectively). The geff value is also large for an integer-spin 
system, since one would expect geff≈4S. Thus, the most likely origin of this signal is one or more inter-
Kramer’s doublet fine structure transitions in mononuclear Mn(II). The spectrum also contains an 
intense trough-shaped feature with a minimum at geff=4.2 (165 mT), suggestive of an S=1 non-Kramer’s 
doublet transition. The other two features in the spectrum at 4 K are two six-line patterns with average 
splittings of ~9.0 mT: the pattern at g=2.02 is presumably bleed-over of the intense perpendicular-mode 
signal, whereas the precise origin of the signal centered atg≈4.8 is unclear. Since both observed six-line 
patterns exhibit Curie-law temperature dependence as well as a 9-mT hyperfine splitting, they can be 
confidently assigned to mononuclear Mn(II). 
 
Fig. 3. Parallel-mode EPR spectra of [MnMn(EcMetAP-I)] in 25 mM Bicine buffer (pH 7.5) and 150 mM KCl recorded 
at (a) 4 K, (b) 10 K, (c) 41 K, and (d) 70 K. Trace (e) is a high-resolution scan recorded at 50 K. Spectra were recorded 
at 20 mW microwave power, with 0.8 mT (a–d) or 0.4 mT (e) magnetic field modulation 
The parallel-mode spectra of [MnMn(EcMetAP-I)] recorded at 41 K and 70 K are shown in Fig. 3c and 
Fig. 3d, respectively. The spectra differ considerably from those recorded at 4 and 10 K (Fig. 3a and 
Fig. 3b). At 41 K (Fig. 3c) the lowest field feature is significantly weaker than at 4 K and at 70 K it is not 
visible. The two six-line patterns, which were clearly visible at 4 and 10 K, are still present but the g≈4.8 
six-line signal is now obscured by other features. This feature can be visualized by Fourier filtering or 
polynomial subtraction of higher resolution spectra and is evident as an apparent splitting of the 
minimum feature at geff=4.2 (165 mT) and as structure on the small feature at geff=5.5 (125 mT). A 
number of features assignable to integral spin systems are present in the 41 K spectrum. There is a 
minimum feature at geff=4.2 (165 mT) which is suggestive of S=1, a peak at geff=8.0 (85 mT) which 
suggests S=2, a shoulder at geff=12 (58 mT), and a broad feature extending out of zero field that exhibits 
a minimum atgeff=18 that could arise from either S=4 or S=5 or both. A quantitative temperature 
dependence of most of the features was not attempted as the signals overlap extensively; however, 
examination of Fig. 3 provides some useful information. The expected relative contributions to the 
spectrum from the S=1, 2 ... i spin multiplets are shown graphically in Fig. 4 for a system with J=7.0 cm−1. 
As is evident from Fig. 4, the relative contributions from the higher spin multiplets increase with 
temperature. The minimum in the parallel-mode EPR spectrum of [MnMn(EcMetAP-I)] at geff=18 is weak 
at 41 K but is pronounced at 70 K. In contrast, the minimum feature at geff=4.2 diminishes in intensity 
upon raising the temperature to 71 K. Furthermore, this feature is the only one ascribable to an integral 
spin system in the 4 K spectrum. These observations are entirely consistent with the assignment of 
the geff=18 feature to either S=4 or 5, and to the assignment of the geff=4.2 feature to S=1. The shoulder 
in the 41 K spectrum at geff=12 (58 mT) is resolved into a peak at 70 K, consistent with the doubling of 
intensity expected for an S=3 spin state. Thus the assignments of the features in this spectrum on the 
basis of their resonance positions are supported by their temperature dependences. 
 
Fig. 4. Relative contributions to the parallel-mode EPR spectrum of [MnMn(EcMetAP-I)] from the S=1, 2, 3, 4, 5 
... i spin multiplets (a–e) for a system with J=7.0 cm−1 
The most interesting feature observed in the parallel-mode EPR spectrum is a multiline signal centered 
about geff=8.0 (Fig. 3c), and the multiline signal can be clearly observed superimposed upon the broader 
features in the signal. The lines were split by ~4.5 mT, a hyperfine splitting similar to the multiline signal 
observed in the perpendicular-mode spectrum. A hyperfine pattern consisting of 11 lines separated by 
4.5 mT and with intensity ratios of 1:2:3:4:5:7:5:4:3:2:1 would be indicative of two spin-coupled Mn(II) 
ions. However, because of the presence of the broader signals, the precise number of lines in the 
experimental spectrum and their relative intensities were difficult to estimate. Thus, it appears that the 
fine structure on the geff=8.0 feature is due to two exchange-coupled Mn(II) ions. This, in turn, suggests 
that the feature in the perpendicular-mode spectrum at geff=2.39 (289 mT; Fig. 2) that exhibits the 
4.4 mT multiline splitting is also due to spin-coupled Mn(II) ions. 
Each of the excited-state spin levels of a spin-coupled dinuclear Mn(II) system, S=1, 2, 3, 4, 5, can 
potentially exhibit features in the EPR spectrum. To obtain structural and electronic information about 
the small portion of spin-coupled Mn(II) ions in [MnMn(EcMetAP-I)], the transitions responsible for at 
least some of the features in the EPR spectrum need to be identified. The features at geff=2.39 (289 mT) 
and 1.60 (430 mT) were chosen for study because they were the most intense and because the multiline 
pattern on the geff=2.39 signal was clear. Spectra were recorded over the temperature range 3.8–150 K 
and the g=2.02 six-line signal was eliminated by subtracting proportions of the 3.8 K signal, which 
exhibited no excited state features, from signals recorded at higher temperature. Thus, the temperature 
dependence of the geff=2.39 and geff=1.60 signals could be measured and the results are shown in Fig. 5. 
The temperature dependence of the g=2.02 six-line signal was also measured and clearly follows a 
1/T Curie-law dependence (Fig. 5). In contrast, the geff=2.39 and geff=1.60 features exhibited a complex 
temperature dependence. For a spin ladder S=0, 1 ... i, the expected temperature-dependent weighted 
contribution to the EPR spectrum can be expressed by Eq. 1: 
 
Fig. 5. EPR intensity versus temperature plot for g≈2 signal (triangles) and for the resonances at 288 and 432 mT 
(circles). The open and solid circles represent data from two different samples. The line through the triangles is a fit 
to Curie behavior and the line through thecircles is a fit to the Boltzmann distribution, 
assuming J=7.1 cm−1 and S=2. Inset: temperature-weighted data and fit 
𝑛𝑛𝑠𝑠(𝑇𝑇) = �(2𝑆𝑆 + 1) 𝑒𝑒𝑒𝑒𝑒𝑒 �−𝑆𝑆(𝑆𝑆 + 1)𝐽𝐽𝑘𝑘𝑇𝑇 �� /{�(2𝑆𝑆𝐼𝐼 +)exp [−𝑆𝑆(𝑆𝑆𝑖𝑖 + 1)𝐽𝐽𝑘𝑘𝑇𝑇 ]} 
𝐼𝐼
   
where ns(T) is the fractional population of the spin state S, S i =0, 1, 2, 3, 4, 5, and J is the exchange 
coupling between the two Mn(II) ions. A graphic display of the consequences of this expression is given 
as Fig. 4. The data for both the geff=2.39 and geff=1.60 features of [MnMn(EcMetAP-I)] were best 
simulated assuming a quintet S=2 spin state with J≈7.0 cm−1(Fig. 5). Attempts to fit the temperature 
dependence of the intensities of the geff=2.39 andgeff=1.60 features to either an S=1 state or a mixed 
triplet-quintet population were entirely unsuccessful, whereas the fit to a pure S=2 state is clearly very 
good over a wide temperature range. Thus the contribution to the resonances at 289 and 430 mT from 
the triplet S=1 state must be very small. The positions of these quintet state resonances has been shown 
to be a function of the zero-field splitting of that state, D2,41 and in [MnMn(EcMetAP-I)] these 
correspond to a D2 value of −0.175 cm−1. Because of the dipole–dipole component of D2, it is very 
sensitive to the inter-manganese distance, and by comparison with model compound data39 the inter-
manganese distance in [MnMn(EcMetAP-I)] was estimated to be 3.1 Å. This value is in very good 
agreement with the crystallographically determined cobalt–cobalt distance of 3.2 Å for [CoCo(EcMetAP-
I)].15,42 
EPR spectroscopy of Mn(II)-substituted EcMetAP-I in the presence of fumagillin 
In order to determine how the anti-angiogenesis agent fumagillin interacts with the Mn(II)-active site 
of EcMetAP-I, both MALDI-TOF mass spectrometry and EPR spectroscopy were used to investigate 
fumagillin binding. In the MALDI-TOF mass spectrum of [MnMn(EcMetAP-I)] a symmetric peak was 
observed at Mr=29,335±10. On the other hand, the MALDI-TOF mass spectrum of [MnMn(EcMetAP-I)]-
fumagillin provided a second symmetric peak at Mr=29,786±10, which is 451 Da larger than that 
observed for the purified, native form of EcMetAP-I. This change in mass is in good agreement with the 
mass of fumagillin, which is 458.6 Da, and indicates that fumagillin is covalently bound to 
[MnMn(EcMetAP-I)]. The identical sample used in the mass spectrometry experiment was also used to 
record the EPR spectrum of [MnMn(EcMetAP-I)]-fumagillin (Fig. 6b). The signal at g≈2, which makes up 
the bulk of the Mn(II) in the sample, is identical to that of the uncomplexed Mn(II)-loaded enzyme. The 
most marked change in the EPR spectrum of [MnMn(EcMetAP-I)]-fumagillin is a shift in the 4.5 mT 
multiline signals by 2.0 mT in the region 260–315 mT (Fig. 7A). The resolution of the experiment is well 
within this value and also the position of the internal standard, provided by the sharp feature due to 
mononuclear Mn(II) at 321.8 mT, is identical in both spectra. Furthermore, measurement of the relative 
intensities of these multiline splittings reveals that the lines in the EPR spectrum of EcMetAP-I treated 
with fumagillin are on average 30% more intense than those of untreated enzyme (Fig. 6). This implies a 
decrease in the g-strain of the Mn(II) centers in [MnMn(EcMetAP-I)] upon fumagillin binding and, thus, a 
decrease in the vibrational freedom compared to the untreated [MnMn(EcMetAP-I)]. A final difference 
is the observation of a weak but detectable multiline splitting pattern in the 387–434 mT region in the 
fumagillin-treated [MnMn(EcMetAP-I)] enzyme (Fig. 7B). This pattern is not detectable in untreated 
[MnMn(EcMetAP-I)] enzyme, presumably because of the line broadening due to the higher the g-strain. 
Thus the EPR data indicate that binding of fumagillin does not alter the mononuclear Mn(II) in the active 
site of EcMetAP-I, and only slightly perturbs the spin coupling between the two Mn(II) ions in the minor 
signal due to dinuclear Mn(II) centers. 
 
Fig. 6. EPR spectra of [MnMn(EcMetAP-I)] in 25 mM Bicine buffer (pH 7.5) and 150 mM KCl at 41 K: (a) native 
enzyme and (b) in the presence of 10 equiv of fumagillin. Parallel-mode EPR spectra of [MnMn(EcMetAP-I)] in 
25 mM Bicine buffer (pH 7.5) and 150 mM KCl recorded at 41 K: (c) native enzyme and (d) in the presence of 
10 equiv of fumagillin. The traces above or below the spectral traces have been magnified 20 or 40 times, 
respectively, highlighting the 4.4 mT-split multiline signals 
 
Fig. 7A, B. EPR spectra of [MnMn(EcMetAP-I)] in 25 mM Bicine buffer (pH 7.5) and 150 mM KCl at 41 K. A 250–
330 mT region where the solid line is [MnMn(EcMetAP-I)] and the dashed line is [MnMn(EcMetAP-I)]+fumagillin. 
The traces above the spectral traces have been magnified 200 times, highlighting the shift in the 4.4-mT-split 
multiline signals. B 350–450 mT region of [MnMn(EcMetAP-I)]+fumagillin. The trace above the spectral trace has 
been magnified 200 times 
Discussion 
Amide bond hydrolysis is a common enzymological reaction and the same chemistry can be catalyzed by 
several different metalloenzymes, including aminopeptidases, carboxypeptidases, endopeptidases, β-
lactamases, ureases, and penicillin amidases.43 Many of these enzymes utilize Zn(II) ions in their catalytic 
active site; however, several have been shown to be partially active or even hyperactive with one or 
more first-row transition metal ions, ranging from Mn(II) to Zn(II). Whole-cell studies on EcMetAP-I 
suggested that the in vivo metal ion for all MetAPs was either Fe(II) or Mn(II).25 Recently, the 
physiologically relevant metal ion forHsMetAP-II was assigned as Mn(II) using Mn(II)-specific synthetic 
inhibitors to probe intracellular HsMetAP-II.23 That Mn(II) can activate EcMetAP-I24 is not surprising since 
the Mn(II)-dependant aminopeptidase P from E. coli (AMPP) has active site ligands that are identical to 
those of MetAPs. Interestingly, AMPP has been suggested to be a Mn(II)-dependent enzyme.44,45 In 
order to gain insight into the metal binding properties of EcMetAP-I, we have recorded EPR spectra of 
the Mn(II)-loaded forms. 
High-spin octahedral Mn(II) ions posses an 6S electronic ground state that can be split by zero-field 
effects when Mn(II) is placed in a ligand field.46 Zero-field splitting produces three Kramer’s doublets 
(Ms=±1/2, ±3/2, ±5/2) whose degeneracy is removed in the presence of a magnetic field. The result of this 
splitting is five allowed (ΔMs=±1) EPR transitions. Coupling of the 55Mn nuclear spin (I=5/2) to the 
electronic spin further complicates the observed EPR spectra and results in a six-fold hyperfine splitting 
pattern that produces 30 possible allowed (ΔMs=±1 and ΔMI=0) transitions. Additional complications 
result from the outer fine-structure transitions (±5/2→±3/2 and ±3/2→±1/2) that are not usually well 
resolved for highly anisotropic protein coordination environments. The most distinctive EPR signature 
for a high-spin Mn(II) center is the (+1/2→−1/2) fine-structure transition that is nearly isotropic and 
typically gives rise to an intense signal at g=2 with a resolved six-fold hyperfine splitting pattern. The 
magnetic spin levels of a Mn(II) ion can be described by the spin hamiltonian: 
𝐻𝐻 = 𝑔𝑔𝑔𝑔𝐁𝐁 ∙ 𝐒𝐒 + 𝐷𝐷 �𝐒𝐒𝑧𝑧2 − 3512� + 𝐸𝐸�𝐒𝐒𝑥𝑥2 − 𝐒𝐒𝑦𝑦2� + A𝐒𝐒𝐒𝐒 
where D and E have their usual meanings. It has been previously reported that significant changes in the 
nuclear hyperfine coupling constant, A, reflects covalency changes in metal–ligand interactions.35,47 The 
X-band EPR spectrum of the Mn(II)-loaded EcMetAP-I ([MnMn(EcMetAP-I)]) at 4 and 41 K reveals a 
strong hyperfine split signal centered at g=2, characteristic of the (+1/2→−1/2) transition. As a control, the 
X-band EPR spectra of [Mn(H2O)6]2+ in buffer were recorded and these data revealed that the observed 
signals are distinct from those obtained for [MnMn(EcMetAP-I)] samples. The hyperfine coupling 
constant, A, measured directly from the spacing of the most intense signals about g=2.02, is ~9.5 mT. 
This is consistent with Mn(II) ions being coordinated by oxygen- and nitrogen-containing ligands.35 The 
signal centered about g≈4.0 with resolvable 55Mn hyperfine splitting (A=95 G) definitively assigns it to 
the Mn(II) ions in EcMetAP-I and not an Fe(III) impurity. Similar signals have been previously observed 
for very anisotropic Mn(II) centers in proteins and were assigned to a ΔMs=±2 transition.35 
The EPR spectrum of Mn(II)-loaded EcMetAP-I suggests that some proportion of the Mn(II) inEcMetAP-I 
is mononuclear. However, multiple lines of evidence from the EPR data exist for a significant population 
of dinuclear Mn(II) in EcMetAP-I; the similarity of resonance positions to inorganic exchange-coupled 
Mn(II) species, their temperature dependences, the parallel mode data, and the resolved 4.5 mT 
multiline hyperfine pattern all indicate dinuclear Mn(II). Recently it was reported that EcMetAP-I 
contains a high- and a low-affinity metal binding site for Fe(II) and Mn(II) and that these enzymes are 
maximally active when only one metal binding site is occupied.24,25 On the basis of the similarity of the 
EPR signals of EcMetAP-I with both one and two equivalents of Mn(II), it seems likely that there exists 
both a dinuclear Mn(II) and a mononuclear Mn(II) associated with EcMetAP-I, at least at the high 
concentrations used for spectroscopy and crystallography. Since X-ray crystallographic data suggest a 
dinuclear active site can form in EcMetAP-I, the EPR-detected dinuclear center almost certainly 
constitutes the active site. Activity and EPR measurements suggest that the dinuclear site is formed by 
the cooperative binding of two Mn(II) ions, and the EPR signal due to mononuclear Mn is clearly distinct 
from that of Mn(II) in buffer. It is, therefore, more likely that the mononuclear species is a distinct Mn(II) 
ion associated with the protein rather than an Mn-depleted active site. 
An important class of MetAP inhibitor based on natural products of fungal origin comprise fumagillin, 
ovalicin, and TNP-470. Ovalicin and a synthetic analog of fumagillin (TNP-470) have been shown to 
preferentially inhibit endothelial cell growth in tumor vasculature in vivo.48 Based on fumagillin-specific 
affinity reagents and mass spectrometric studies on MetAP-fumagillin complexes, MetAPs were 
identified as the specific target of fumagillins.26,49 The mode of inhibition was shown to be via the 
formation of a covalent bond between a conserved histidine residue in MetAPs and an epoxide carbon 
moiety on fumagillin.26,28,49,50 Confirmation that fumagillin reacts with EcMetAP-I comes from mass 
spectrometric and N-terminal sequence analysis, which indicated that fumagillin covalently binds to an 
active-site histidine residue (His79) that is not a ligand at the dinuclear active-site cluster.28 In order to 
gain structural information on the interaction between the Mn(II) active site of EcMetAP-I and the anti-
angiogenesis drug fumagillin, X-band EPR spectra of [MnMn(EcMetAP-I)] were recorded after reaction 
with fumagillin. That fumagillin was covalently bound to the Mn(II)-loaded EcMetAP-I enzyme was 
verified by MALDI-TOF spectrometric analysis of the EPR samples, which revealed a mass shift of 451 Da, 
in excellent agreement with the mass of fumagillin (458 Da). Interestingly, and perhaps surprisingly, no 
significant change in the X-band EPR spectra recorded in either the perpendicular or parallel modes 
were observed, except for a 2.5 mT change in the position of the 4.5 mT multiline signals observed on 
the g≈2.39 signal. These data strongly suggest that upon fumagillin binding, no protein-derived ligand 
atoms or metal-bound water molecules are displaced. In addition, the single oxygen atom bridge 
between the minor dinuclear species is not displaced since this would have likely resulted in a change in 
the Mn–Mn distance that would be expected to result in a perturbation of the Heisenberg exchange 
interaction. Moreover, these data are also inconsistent with the replacement of the bridging water 
molecule with a bridging alkoxide atom from fumagillin, since such a change would clearly alter the 
Heisenberg exchange interaction. 
Combination of the EPR spectroscopic results for the fumagillin-bound [MnMn(EcMetAP-I)] with the 
recent X-ray crystal structure of the type-II MetAP from H. sapiens complexed with fumagillin, at 1.8 Å 
resolution, reveals some interesting similarities and differences. The epoxide-bearing side chain of 
fumagillin occupies the putative substrate-binding pocket ofHsMetAP-II. The long unsaturated side-chain 
is analogous to the COOH-terminal peptide chain in the X-ray structure of a substrate analog inhibited 
form of EcMetAP-I.15,42 The crystallographic results also verify that a covalent bond is formed between 
the reactive ring epoxide of fumagillin and His231 in the active site of the type-II MetAP. The oxygen 
atom liberated from the breaking of the epoxide bond is 3.28 Å away from Co1, the Co(II) ion bound by 
His331, Glu364, and the two bridging carboxylate residues Asp262 and Glu459. This alkoxide oxygen 
atom was suggested to be directly coordinated to Co1. The EPR results presented herein clearly indicate 
that the alkoxide oxygen atom of fumagillin is not coordinated to either the mononuclear Mn(II) center 
in the active site of EcMetAP-I or the dinuclear component, contrary to that suggested by Liu et al.17 
Closer inspection of the X-ray crystal structure of HsMetAP-II complexed by fumagillin indicates that the 
approximate location of the alkoxide oxygen of fumagillin is where a water molecule resided at >3 Å 
from the Co(II) ion in the uncomplexed structure. Therefore, we propose that the oxygen atom liberated 
upon the addition of fumagillin to EcMetAP-I displaces the water molecule that bridges between His178 
and the water molecule bridging between the two Co(II) ions as revealed in the X-ray structure of 
native EcMetAP-I (Fig. 8). This structure is also consistent with EXAFS data reported for the Co(II)-loaded 
form of EcMetAP-I in the presence of fumagillin.21 Thus, fumagillin does notprovide a ligand to either 
metal ion in the dinuclear active site, nor does it bridge between the two metal ions, but instead slightly 
perturbs the Mn(II) centers through a H-bonding interaction with a bound water molecule. Since 
fumagillin has two reactive epoxide moieties, it is quite cytotoxic, probably due to alkylation of other 
biomolecules within the cell. Therefore, understanding the molecular mechanism of the MetAP-
catalyzed cleavage of N-terminal methionine residues, as well as the binding mode of known anti-
angiogenesis drugs, will facilitate the rational design of new, more potent MetAP inhibitors with 
improved in vivo stability, specificity, and lower cytotoxicity. 
 
Fig. 8. Proposed binding scheme for fumagillin to the active site of EcMetAP-I 
Notes 
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